Wilderness & environmental medicine · 2011
Improving sleep at altitude: a comparison of therapies.
Сравнительное исследованиеСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rodway George W, Edsell Mark E, Wong Bob, Windsor Jeremy S, Caudwell Xtreme Everest Research Group
Аннотация
OBJECTIVE: This study aimed to compare 3 treatment modalities during sleep at an altitude of 5300 m to identify strategies for reducing the incidence of periodic breathing at high altitude.
METHODS: Fifteen trekkers, with identical ascent profiles and no signs or symptoms of altitude illness, served as subjects. All study participants arrived at 5300 m after a gradual ascent from 1300 m. On their second night at 5300 m, subjects were randomly assigned (with a computer-based random assignment procedure) to 1 of 4 different treatment groups: control (n = 4); 1 L/min O(2) via a demand system during sleep (n = 3); 1 L/min O(2)/CO(2) mix (1.5% CO(2)) via a demand system during sleep (n = 4); or 125 mg acetazolamide 30 minutes before bedtime (n = 4). Heart rate, respiration rate, blood oxygen saturation, tidal volume, minute volume, and apnea hypopnea index were measured.
RESULTS: Upon comparing the 4 groups, there were no statistically significant differences between the variables. One-way analysis of variance indicated a trend toward statistical significance for SaO(2) between groups (F = 2.9, P = .08), and Tukey Honestly Significant Difference (HSD) post hoc tests indicated a trend in the SaO(2) difference between the 1 L/min oxygen and control groups (P = .07). While 1-way analysis of variance suggested no difference for respiratory rate between groups (F = 2.5, P = .1), Tukey HSD indicated a trend in statistical difference of the respiratory rate between 1 L/min O(2) and 1 L/min O(2)/CO(2) mixture (P = .08).
CONCLUSIONS: These statistical trends found between control and treatment groups indicate that further study is warranted.
METHODS: Fifteen trekkers, with identical ascent profiles and no signs or symptoms of altitude illness, served as subjects. All study participants arrived at 5300 m after a gradual ascent from 1300 m. On their second night at 5300 m, subjects were randomly assigned (with a computer-based random assignment procedure) to 1 of 4 different treatment groups: control (n = 4); 1 L/min O(2) via a demand system during sleep (n = 3); 1 L/min O(2)/CO(2) mix (1.5% CO(2)) via a demand system during sleep (n = 4); or 125 mg acetazolamide 30 minutes before bedtime (n = 4). Heart rate, respiration rate, blood oxygen saturation, tidal volume, minute volume, and apnea hypopnea index were measured.
RESULTS: Upon comparing the 4 groups, there were no statistically significant differences between the variables. One-way analysis of variance indicated a trend toward statistical significance for SaO(2) between groups (F = 2.9, P = .08), and Tukey Honestly Significant Difference (HSD) post hoc tests indicated a trend in the SaO(2) difference between the 1 L/min oxygen and control groups (P = .07). While 1-way analysis of variance suggested no difference for respiratory rate between groups (F = 2.5, P = .1), Tukey HSD indicated a trend in statistical difference of the respiratory rate between 1 L/min O(2) and 1 L/min O(2)/CO(2) mixture (P = .08).
CONCLUSIONS: These statistical trends found between control and treatment groups indicate that further study is warranted.